GC treatment duration for <90 and 90 to 360 days is associated with a higher risk of cumulative SI compared to nonexposed, especially the first year but also up to two years since first visit in RA patients. Maximum RR for <90 days is observed at 8 months since first visit (RR:… https://t.co/ecK2ylqrRk https://t.co/IQ5QQjExYQ

• https://twitter.com/i/web/status/1801177052466262294
• https://twitter.com/synovialjoints/status/1801177052466262294/photo/1

Poster tours at #EULAR2024. A third of seropositive RA patients with long disease duration had subclinical lung abnormalities. This pilot study showed the potential role of lung ultrasound for the screening of subclinical ILD among these patients. Abstract 070 @RheumNow https://t.co/ypAh4idV3j

• https://twitter.com/synovialjoints/status/1801175696317808811/photo/1

OP0072 @RheumNow #EULAR2024 Effects of #Upadacitinib or #Adalimumab on pain in #RA SELECT-COMPARE Phase 3 study UPA & ADA led to improvements in pain vs PBO PtGA & TJC28 pain improvement similar between UPA & ADA ➡️ UPA may be more effective in control of pain than ADA in RA

#Vaccinations against #herpes #zoster in #MTX +#Upadacitinib Pts ▶️ #Shingrix works 👍Pts followed to 60 months #EULAR2024 @eular_org @RheumNow #OP0020 https://t.co/8ORC3Nd2FK

• https://twitter.com/drdavidliew/status/1800906791502647424

OP0018 @RheumNow #EULAR2024 🔎 Study looked at early RA patient trajectories through time-independent disease state 📊 Authors demonstrated 4⃣ trajectories in early RA 🦴 Inflammation in joints, blood & poor response are main discriminatory factors https://t.co/IeDIU3jg9B

• https://twitter.com/DrMiniDey/status/1800970427642298680/photo/1

➡️ OP0064 @RheumNow #EULAR2024 ➡️ Non-articular pain (NAP) at early RA diagnosis & evolution over the first yr of RA treatment ➡️ NAP, esp regional NAP, common in early RA during 1st yr ➡️ NAP in axial, both upper quadrants and both lower quadrants common https://t.co/FOGcS05Z25

• https://twitter.com/DrMiniDey/status/1800968672300892171/photo/1

OP0086 #EULAR2024 @RheumNow #EULARBest Pain & remission/low disease activity at 3m in pts with #RA in RA-BE-REAL Pts taking #baricitinib more likely to achieve pain control vs TNFi/other mode of action 1/2 pts achieving remission/LDA & had bari achieved ≥70% pain relief.